Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: A cross-study analysis

Addictive Behaviors

Volumn 36, Issue 12, 2011, Pages 1288-1291

  Hughes, John R ^a   Russ, Cristina I ^b   Arteaga, Carmen E ^b   Rennard, Stephen I ^c  

^a UNIVERSITY OF VERMONT   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Quit date; Smoking cessation; Varenicline

Indexed keywords

PLACEBO; VARENICLINE;

ARTICLE; DRUG EFFICACY; HUMAN; INCIDENCE; MOTIVATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SMOKING CESSATION;

BENZAZEPINES; DOUBLE-BLIND METHOD; HUMANS; MOTIVATION; MULTICENTER STUDIES AS TOPIC; NICOTINIC AGONISTS; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053178941     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2011.08.001     Document Type: Article

References (24)

1. Balmford J., Borland R., Burney S. The influence of having a quit date on prediction of smoking cessation outcome. Health Education Research 2010, 25:698-706.
2. Bolliger C., Issa J., Posadas-Valay R., Safwat T., Abreu P., Correia E., et al. A randomized trial of varenicline for smoking cessation in Latin America, Africa and the Middle East. American Journal of Respiratory and Critical Care Medicine 2010, 181:A2648.
3. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2008, 3:CD006103.
4. Cooper J., Borland R., Yong H., McNeill A., Murray R., O'Connor R., et al. To what extent do smokers make spontaneous quit attempts and what are the implications for smoking cessation maintenance? Findings from the International Tobacco Control Four country survey. Nicotine & Tobacco Research 2010, 12:S51-S57.
5. Fagerström K., Hughes J.R. Varenicline in the treatment of tobacco. Neuropsychiatric Disease and Treatment 2008, 4:1-11.
6. Ferguson S., Shiffman S., Gitchell J., Sembower M., West R. Unplanned quit attempts - Results from a U.S. sample of smokers and ex-smokers. Nicotine & Tobacco Research 2009, 11:827-832.
7. Fiore M., Jaen C., Baker T., Bailey W., Benowitz N., Curry S., et al. U.S. Department of Health and Human Services: Public Health Service. (2008). Treating Tobacco Use and Dependence: Clinical Practice Guideline 2008, Retrieved from, Accessed 19 April, 2011. http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf.
8. Gollwitzer P., Sheeran P. Implementation intentions and goal achievement: A meta-analysis of effects and processes. Advances in Experimental Social Psychology 2006, 38:69-119.
9. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. Journal of the American Medical Association 2006, 296(1):47-55.
10. Hallaq J. The pledge as an instrument of behavioral change. The Journal of Social Psychology 1976, 98:147-148.
11. Jorenby D., Hays J., Rigotti N., Azoulay S., Watsky E., Williams K., et al. Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. Journal of the American Medical Association 2006, 296:56-63.
12. Larabie L.C. To what extent do smokers plan quit attempts?. Tobacco Control 2005, 14:425-428.
13. 2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics 2007, 29:1040-1056.
14. Oncken C., Gonzales D., Nides M., Rennard S., Watsky E., Billing C., et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine 2006, 166:1571-1577.
15. Rennard, S., Hughes, J. R., Cinciripini, P. M., Kralikova, E., Raupach, T., Arteaga, C., et al. (in press). A randomized, placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine and Tobacco Research.
16. Rigotti N., Pipe A., Benowitz N., Arteaga C., Garza D., Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 2010, 121:221-229.
17. Segan C., Borland R., Greenwood K. Do Transtheoretical Model measures predict the transition from preparation to action in smoking cessation?. Psychology and Health 2002, 17:417-435.
18. Slavin R.E. Best evidence synthesis: An intelligent alternative to meta-analysis. Journal of Clinical Epidemiology 1995, 48:9-18.
19. Spilker B. Guide To Clinical Trials 2000, Lippincott Williams & Wilkins, Philadephia, PA.
20. Tashkin D., Rennard S., Hays J., Ma W., Lawrence D., Lee T. Effects of varenicline on smoking cessation in mild-to-moderate COPD: A randomized controlled trial. Chest 2011, 139:591-599.
21. Tsai S., Cho H., Cheng H., Kim C., Hsueh K., Billing C., et al. A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clinical Therapeutics 2007, 29:1027-1039.
22. Wang C., Wiao D., Chan K., Pothirat C., Garza D., Davies S. Varenicline for smoking cessation: A placebo-controlled, randomized study. Respirology 2009, 14:384-392.
23. West R., Sohal T. Catastrophic pathways to smoking cessation: Findings from a national survey. British Medical Journal 2006, 302:458-460.
24. Wolfe R., Hanley J. If we're so different, why do we keep overlapping? When 1 plus 1 doesn't make 2. Canadian Medical Association Journal 2002, 166:65-66.